BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35965590)

  • 21. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.
    Gringeri E; Gambato M; Sapisochin G; Ivanics T; Lynch EN; Mescoli C; Burra P; Cillo U; Russo FP
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32380750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways.
    Chen T; Li K; Liu Z; Liu J; Wang Y; Sun R; Li Z; Qiu B; Zhang X; Ren G; Xu Y; Zhang Z
    Mol Ther; 2021 Jun; 29(6):2134-2150. PubMed ID: 33601056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunobiology of cholangiocarcinoma.
    Loeuillard E; Conboy CB; Gores GJ; Rizvi S
    JHEP Rep; 2019 Oct; 1(4):297-311. PubMed ID: 32039381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
    Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
    Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.
    Zhang Y; Ma Z; Li C; Wang C; Jiang W; Chang J; Han S; Lu Z; Shao Z; Wang Y; Wang H; Jiao C; Wang D; Wu X; Shen H; Wang X; Hu Z; Li X
    Nat Commun; 2022 Jun; 13(1):3061. PubMed ID: 35650238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes.
    Li C; Bie L; Chen M; Ying J
    Explor Target Antitumor Ther; 2023; 4(6):1310-1327. PubMed ID: 38213535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities.
    Hang H; Jeong S; Sha M; Kong D; Xi Z; Tong Y; Xia Q
    Ann Transl Med; 2019 Dec; 7(23):744. PubMed ID: 32042760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Holliday junction-recognizing protein promotes cell proliferation and correlates with unfavorable clinical outcome of hepatocellular carcinoma.
    Hu B; Wang Q; Wang Y; Chen J; Li P; Han M
    Onco Targets Ther; 2017; 10():2601-2607. PubMed ID: 28553125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
    Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
    Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the management of cholangiocarcinoma.
    Zori AG; Yang D; Draganov PV; Cabrera R
    World J Hepatol; 2021 Sep; 13(9):1003-1018. PubMed ID: 34630871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
    Fontugne J; Augustin J; Pujals A; Compagnon P; Rousseau B; Luciani A; Tournigand C; Cherqui D; Azoulay D; Pawlotsky JM; Calderaro J
    Oncotarget; 2017 Apr; 8(15):24644-24651. PubMed ID: 28445951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.
    Hu Z; Huang G; Sadanandam A; Gu S; Lenburg ME; Pai M; Bayani N; Blakely EA; Gray JW; Mao JH
    Breast Cancer Res; 2010; 12(2):R18. PubMed ID: 20211017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
    Li L; Li X; Meng Q; Khan AQ; Chen X
    Med Sci Monit; 2018 May; 24():3050-3055. PubMed ID: 29743473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
    Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
    BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of liver transplantation for cholangiocarcinoma.
    Twohig P; Peeraphatdit TB; Mukherjee S
    World J Gastrointest Surg; 2022 Jan; 14(1):1-11. PubMed ID: 35126858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
    Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
    Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.